Dr. Jennifer Doudna won the Nobel Prize for pioneering gene-editing technology CRISPR. Today, Scribe Therapeutics, the company she co-founded, just raised $128.7 million in its IPO for a much bigger ambition: using CRISPR to prevent heart disease. Scribe Therapeutics co-founder and Scientific Advisor Jennifer Doudna joins Ed Ludlow on "Bloomberg Tech" from the Nasdaq.
--------
Like this video? Subscribe to Bloomberg Technology on YouTube:
Watch the latest full episodes of "Bloomberg Technology" with Caroline Hyde and Ed Ludlow here:
Get the latest in tech from Silicon Valley and around the world here:
Connect with us on...
X:
Facebook:
Instagram:
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
Listen to the daily Bloomberg Technology podcast here:
More from Bloomberg Business
Connect with us on...
X:
Facebook:
Instagram:
LinkedIn:
TikTok:
|
The AI infrastructure buildout is drivin...
Tricia Scarlata, Head of Education Savin...
Austin became the fastest-growing large ...
The news doesn’t stop when markets close...
The industrials sector of the S&P 500 ha...
WSJ’s Josh Dawsey reviewed the documenta...
✅画面に表示される株価・指数などの数値は【2026年7月23日放送時点】のもので...
✅画面に表示される株価・指数などの数値は【2026年7月23日放送時点】のもので...
Troy Jackson, a former Maine lawmaker, w...
Our investigative reporter Eric Lipton e...
President Trump and his allies have buil...
Paramount Skydance has agreed to delay i...